VitaNova Life Sciences (VNOV) EV to EBITDA (2022 - 2026)

VitaNova Life Sciences has disclosed EV to EBITDA across 3 years of filings, most recently posting 2751.59 for Q2 2026.

• EV to EBITDA for Q2 2026 came in at 2751.59, up 26030.39% year-over-year; the trailing twelve-month figure through Apr 2026 was 2751.59 (up 26030.39% YoY), and the FY2026 annual result was 2751.59, up 26030.39% from the prior year.
• EV to EBITDA for Q2 2026 stood at 2751.59, up from 32.7 in the prior quarter.
• Across five years, EV to EBITDA topped out at 2751.59 in Q2 2026 and bottomed at 10.2 in Q3 2025.
• Average EV to EBITDA over 3 years is 350.14, with a median of 51.93 recorded in 2024.
• The widest annual swing landed in 2025, when EV to EBITDA slumped 88.34%; it then jumped 26030.39% in 2026.
• Year by year, EV to EBITDA stood at 51.93 in 2024, then soared by 83.03% to 95.04 in 2025, then soared by 2795.11% to 2751.59 in 2026.
• The last three EV to EBITDA figures came in at 2751.59 (Q2 2026), 32.7 (Q1 2026), and 95.04 (Q4 2025), per Business Quant data.